GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
The plant is yet to start commercial operations
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
New facility is part of Aptar Pharma’s global expansion program
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
The company has received Form 483 with three observations
Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore
Subscribe To Our Newsletter & Stay Updated
